Evidence map›Paper›PMID 28270146›Full record

ArticleMolecular cancer2017

BMI1, a new target of CK2α.

Soumyajit Banerjee Mustafi, Prabir Kumar Chakraborty, Shailendra Kumar Dhar Dwivedi, Kai Ding, Katherine M Moxley, Priyabrata Mukherjee, Resham Bhattacharya

Open access · goldAbstract read
In one paragraph

Article in Molecular cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. KRCC1: A potential therapeutic target in ovarian cancer.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2020
    Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Soumyajit Banerjee MustafiPeggy and Charles Stephenson Cancer Center (OUHSC), University of Oklahoma Health Science Center, 975 NE 10th Street, BRC-1409B, Oklahoma City, OK, 73104, USA.
Prabir Kumar ChakrabortyPeggy and Charles Stephenson Cancer Center (OUHSC), University of Oklahoma Health Science Center, 975 NE 10th Street, BRC-1409B, Oklahoma City, OK, 73104, USA.
Shailendra Kumar Dhar DwivediPeggy and Charles Stephenson Cancer Center (OUHSC), University of Oklahoma Health Science Center, 975 NE 10th Street, BRC-1409B, Oklahoma City, OK, 73104, USA.
Kai DingDepartment of Biostatistics and Epidemiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Katherine M MoxleyPeggy and Charles Stephenson Cancer Center (OUHSC), University of Oklahoma Health Science Center, 975 NE 10th Street, BRC-1409B, Oklahoma City, OK, 73104, USA.
Priyabrata MukherjeePeggy and Charles Stephenson Cancer Center (OUHSC), University of Oklahoma Health Science Center, 975 NE 10th Street, BRC-1409B, Oklahoma City, OK, 73104, USA.
Resham BhattacharyaPeggy and Charles Stephenson Cancer Center (OUHSC), University of Oklahoma Health Science Center, 975 NE 10th Street, BRC-1409B, Oklahoma City, OK, 73104, USA. Resham-Bhattacharya@ouhsc.edu.
University of Oklahoma Health Sciences Center · US

Funding

TUMOR RESISTANCE MECHANISMS TO ANTI-VEGF THERAPY IN PROSTATE CANCER (Sukyung Woo)P20GM103639 · NIGMS · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI HANNAFON, BETHANY · 2012 to 2022
$21.3M
Cystathionine beta synthase (CBS) and angiogenesisR01HL120585 · NHLBI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI BHATTACHARYA, RESHAM, MUKHERJEE, PRIYABRATA · 2013 to 2017
$2.1M
Bmi-1, a potential therapeutic target in ovarian cancerR01CA157481 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI BHATTACHARYA, RESHAM · 2012 to 2016
$1.6M
Exploiting gold nanoparticle as a probe to identify therapeutic targetsR01CA260449 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI Resham Bhattacharya, Priyabrata Mukherjee · 2022 to 2026
$1.6M
NCI NIH HHS R01 CA157481NCI NIH HHS R01 CA260449NHLBI NIH HHS R01 HL120585NIGMS NIH HHS P20 GM103639
6 · The paper itself

Abstract

backgroundThe polycomb group protein, BMI1 plays important roles in chromatin modification, stem cell function, DNA damage repair and mitochondrial bioenergetics. Such diverse cellular functions of BMI1 could be, in part, due to post-translational modifications, especially phosphorylation. To date, AKT has been reported as a kinase that by site specific phosphorylation of BMI1 modulates its oncogenic functions.

methodsImmunoprecipitation in conjunction with kinase assay and mass spectrometry was used to determine association with and site specific phosphorylation of BMI1 by CK2α. Functional implications of the BMI1/CK2α axis was examined in cancer cells utilizing siRNA and exogenous gene expression followed by biochemical and phenotypic studies. Correlations between expression of CK2α and BMI1 were determined from cell lines and formalin fixed paraffin embedded tissues representing the normal fallopian tube epithelium and high grade serous ovarian cancer samples.

resultsHere we report that CK2α, a nuclear serine threonine kinase, phosphorylates BMI1 at Serine 110 as determined by in-vitro/ex-vivo kinase assay and mass spectrometry. In ovarian cancer cell lines, expression of CK2α correlated with the phospho-species, as well as basal BMI1 levels. Preventing phosphorylation of BMI1 at Serine 110 significantly decreased half-life and stability of the protein. Additionally, re-expression of the phosphorylatable but not non-phosphorylatable BMI1 rescued clonal growth in endogenous BMI1 silenced cancer cells leading us to speculate that CK2α-mediated phosphorylation stabilizes BMI1 and promotes its oncogenic function. Clinically, compared to normal fallopian tube epithelial tissues, the expression of both BMI1 and CK2α were significantly higher in tumor tissues obtained from high-grade serous ovarian cancer patients. Among tumor samples, the expression of BMI1 and CK2α positively correlated (Spearman coefficient = 0.62, P = 0.0021) with each other.

conclusionTaken together, our findings establish an important regulatory role of CK2α on BMI1 phosphorylation and stability and implicate the CK2α/BMI1 axis in ovarian cancer.

Indexed as

Casein Kinase IICell Line, TumorFemaleHumansMitogen-Activated Protein Kinase 7MutationOvarian NeoplasmsPhosphorylationPolycomb Repressive Complex 1Protein BindingProteolysisSignal TransductionBMI1 protein, humanCasein Kinase IICSNK2A1 protein, humanMitogen-Activated Protein Kinase 7Polycomb Repressive Complex 1Clonal growthFallopian tube epithelial (FTE) cellsFormalin fixed paraffin embedded tissues (FFPE)High-grade serous ovarian cancerKinase assayPhosphorylationPost translational modificationProtein stability

Identifiers

PMID28270146
PMCPMC5341428
OpenAlexW2591622773

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.